Keith M. Kerr - Concepedia

Author

Keith M. Kerr

Aberdeen Royal Infirmary

Also Known As

Babu Naidu, Dziadziuszko, Rafal, K Kerr, K M Kerr, K. Kerr, K. M Kerr, K. M. Kerr, K.M Kerr, K.M. KERR, K.M. Kerr

430

Publications

55.8K

Citations

H-Index

120

Concepts

All Affiliations

Aberdeen Royal Infirmary University of Aberdeen Imperial College London Brigham and Women's Hospital The University of Texas MD Anderson Cancer Center

About

Keith M. Kerr is an author at Aberdeen Royal Infirmary specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	53	97	21.3K
2	Health Sciences	18	22	8.9K
3	Engineering	3	3	659
4	Public Health	2	2	96
5	Biology	1	1	39

Keith M. Kerr

163

Publications

35.3K

Citations

H-Index

Page 1

	Year	Citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Silvia Novello, Fabrice Barlési, Raffaele Califano, Annals of Oncology MedicineCancer ManagementPulmonary BlastomaOncologyRadiation Oncology	2016	2.6K
Tracking the Evolution of Non–Small-Cell Lung Cancer Mariam Jamal‐Hanjani, Gareth A. Wilson, Nicholas McGranahan, New England Journal of Medicine	2017	2.3K
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up John B.A.G. Haanen, Franck Carbonnel, Caroline Robert, Annals of Oncology ImmunotoxicologyImmunodeficienciesImmunologyAutoimmunityImmunomodulation	2017	2.3K
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Pieter E. Postmus, Keith M. Kerr, Matthijs Oudkerk, Annals of Oncology Non-small-cell Lung CancerAdvanced Lung DiseaseMedicineCancer ManagementPulmonary Medicine	2017	2.3K
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up David Planchard, Sanjay Popat, Keith M. Kerr, Annals of Oncology	2018	2.2K
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution Christopher Abbosh, Nicolai J. Birkbak, Gareth A. Wilson, Nature	2017	1.8K
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution Nicholas McGranahan, Rachel Rosenthal, Crispin T. Hiley, Cell	2017	1.3K
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, Abigail McElhinny, Dave Stanforth, Journal of Thoracic Oncology Cancer ImmunosurveillanceAdvanced Lung DiseaseMedicineImmunologyPathology	2016	1.2K
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology Neal I. Lindeman, Philip T. Cagle, Dara L. Aisner, Archives of Pathology & Laboratory Medicine	2018	887
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project Ming‐Sound Tsao, Keith M. Kerr, Mark Kockx, Journal of Thoracic Oncology Real-life Clinical SamplesBiomarker (Medicine)Translational MedicineBlueprint Phase 2Immunocytochemical Technique	2018	793

Page 1